Failed Lp(a) drug trial casts shadow over rival cardiovascular therapies

Full data from a closely watched clinical trial showed the drug reduced Lp(a) levels but delivered no cardiovascular benefit, contradicting the hypothesis that lowering Lp(a) improves outcomes. This failure raises uncertainty for rival developers pursuing similar Lp(a)-targeting therapies, potentially resetting expectations for the class. The mechanism's efficacy is now in question, though the result is from a single trial and may not generalize to all agents in the class.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works